Our products
Patients are at the heart of everything we do. Using our expertise and passion for science, we develop innovative solutions that directly address patients’ unmet needs.
Pain is one of the most common reasons why people seek medical help. Experts estimate that tens of millions of people experience moderate to severe pain with no access to adequate treatment. Chronic pain is a widespread health problem and although few people die of pain, many die in pain, and even more live in pain.1,2
Pain has an enormous impact on quality of life: from low functionality to anxiety and depression, the comorbidities associated with chronic pain heavily impact the lives of patients with intractable pain and it is only understandable that patients with chronic pain hold huge hopes for effective and innovative solutions.
- To harness the power of science, we carry out integrated research and development to find innovative solutions for the treatment of pain whether such solutions are drugs or state-of-the-art technologies, our objective is to relieve pain.
- Understanding the patients’ journey is key to our work as it contextualizes our research and helps us understand where we need to create value along that journey from the first onset of symptoms to treatment initiation and beyond.
- Actively involving patients during research and development is key as it enables Grünenthal to integrate real-life experiences into the study design and ultimately, to create solutions that really improve their lives.
We are tirelessly developing life-changing innovations that challenge the status quo.
Working hand-in-hand with patients, academics, healthcare professionals, and policymakers, we are determined to develop unique solutions addressing diseases with high unmet needs. If we can have a significant and real impact on these people’s lives, then we have made their hopes a reality.
1 Treede RD, et al. Pain 2015 Jun;156(6):1003-1007.
2 Pain Alliance Europe, 2017, Survey on Chronic Pain 2017, Diagnosis, Treatment and Impact of Pain.
Product Portfolio Grünenthal Pharma Ltd.
The product information provided on this site is intended for residents of Ireland only.
The links below will direct you to medicines.ie, an external website providing information about medicines in Ireland, including the Patient Information Leaflet (PIL) and the Summary of Product Characteristics (SPC).
The following documents are hosted externally. Grünenthal Pharma Ltd. is not responsible for the content of external sites.
We understand you may wish to report side effects or make a quality complaint. You can do this as follows:
Adverse events & Quality complaint reporting by Healthcare Professionals
Adverse events should be reported to
HPRA Pharmacovigilance, Earls fort Terrace, Dublin 2.
Telephone: +353 1 676 4971
Fax: +353 1 676 2517
Email: medsafety@hpra.ie
Reporting forms and information can be found at www.hpra.ie.
Adverse events should also be reported to Grünenthal Ltd.
Free phone: +44 800 2545540
Email: medicalinformationie@grunenthal.com
Reporting of side effects by patients/carers, members of the public
If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. By reporting side effects, you can help provide more information on the safety of this medicine. You can also report side effects directly to
HPRA Pharmacovigilance, Earls fort Terrace, Dublin 2.
Telephone: +353 1 676 4971.
Fax: +353 1 676 2517.
Email: medsafety@hpra.ie
Reporting forms and information can be found at www.hpra.ie.
Quality complaints should also be reported.
If you report side effects or other issues regarding the safeness or quality of our products directly to Grünenthal Ltd, we will be legally bound to deal with your communication and may have to contact you for clarification purposes. Subsequently, we may have to notify the health authorities.
For patients and members of the public, your information will be forwarded in pseudonymised form, that means no information by which you may be directly identified will be passed on. We may also have to forward this information to our group companies and cooperation partners, to the extent these are likewise obliged to notify their respective health authorities.